0.55
+0.00200003(+0.36%)
Currency In USD
| Previous Close | 0.55 |
| Open | 0.56 |
| Day High | 0.57 |
| Day Low | 0.54 |
| 52-Week High | 8.72 |
| 52-Week Low | 0.46 |
| Volume | 428,717 |
| Average Volume | 21.72M |
| Market Cap | 8.42M |
| PE | 0.73 |
| EPS | 0.75 |
| Moving Average 50 Days | 0.78 |
| Moving Average 200 Days | 1.24 |
| Change | -0.01 |
If you invested $1000 in Scienture Holdings, Inc. (SCNX) since IPO date, it would be worth $73.04 as of December 02, 2025 at a share price of $0.547. Whereas If you bought $1000 worth of Scienture Holdings, Inc. (SCNX) shares 1 year ago, it would be worth $73.04 as of December 02, 2025 at a share price of $0.547.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
GlobeNewswire Inc.
5 hours ago
COMMACK, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through
SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
GlobeNewswire Inc.
Nov 04, 2025 1:05 PM GMT
Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on pro
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
GlobeNewswire Inc.
Oct 23, 2025 12:05 PM GMT
Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMA